Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (13)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

    HemaSphere, Vol. 8, Núm. 10

2023

  1. In-depth blood immune profiling of Good syndrome patients

    Frontiers in Immunology, Vol. 14

2021

  1. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

    Leukemia Research, Vol. 109

2020

  1. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

2018

  1. In-depth proteomic characterization of classical and non-classical monocyte subsets

    Proteomes, Vol. 6, Núm. 1

2016

  1. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma

    Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262

  2. Sensing parasites: Proteomic and advanced bio-detection alternatives

    Journal of Proteomics, Vol. 136, pp. 145-156

2015

  1. Integration of proteomics and transcriptomics data sets for the analysis of a lymphoma B-cell line in the context of the chromosome-centric human proteome project

    Journal of Proteome Research, Vol. 14, Núm. 9, pp. 3530-3540

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

    Journal of Clinical Oncology, Vol. 29, Núm. 12, pp. 1627-1633

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2007

  1. p73 cooperates with Ras in the activation of MAP kinase signaling cascade

    Cell Death and Differentiation, Vol. 14, Núm. 2, pp. 254-265